Neurocrine Biosciences
NBIX
#1310
Rank
NZ$29.39 B
Marketcap
NZ$292.36
Share price
-0.39%
Change (1 day)
32.08%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): NZ$11.51

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$11.48. In 2025 the company made an earnings per share (EPS) of NZ$8.25 an increase over its 2024 EPS that were of NZ$5.78.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$11.5139.59%
2025NZ$8.2542.6%
2024NZ$5.7833.07%
2023NZ$4.3557.76%
2022NZ$2.7569.47%
2021NZ$1.63-78.21%
2020NZ$7.46990%
2019NZ$0.6881.82%
2018NZ$0.38-113.5%
2017NZ-$2.790.62%
2016NZ-$2.7757.28%
2015NZ-$1.7625.61%
2014NZ-$1.4018.84%
2013NZ-$1.18-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.24-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$3.52-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.29 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.57-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.47-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$5.99-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$51.16-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.26-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK